Tyra Biosciences Inc (TYRA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $1.38B
Last updated: Nov 17, 2026 at 4:33 PM ET
Tyra Biosciences Inc (TYRA) Statistics
Tyra Biosciences (TYRA) has a market cap of $1.38B and an enterprise value of $927.37M. Revenue fell 100.00% over the last 12 months from the 12 months before. Its share count is up 15.77% from a year earlier.
Total Valuation
Enterprise value is 32.96% below the market cap, as cash exceeds debt.
| Market Cap | $1.38B |
|---|---|
| Enterprise Value | $927.37M |
| Latest price (Nov 17, 2026) | $19.57 |
Key Dates
The next earnings report is expected on Mar 1, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Mar 1, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | December |
Price Statistics
The stock is up 24.41% over 52 weeks and trades 8.68% below its 50-day average.
| Beta (1Y) | 0.59 |
|---|---|
| 52-Week Change | +24.41% |
| 1-Month Change | +1.19% |
| 3-Month Change | -27.00% |
| 6-Month Change | -42.07% |
| 5-Year Change | -5.90% |
| Total Return (1Y) | +24.41% |
| Total Return (3Y CAGR) | +19.70% |
| Total Return (5Y CAGR) | -3.86% |
| Return vs SPY (1Y) | +10.45% |
| Max Drawdown (1Y) | -53.24% |
| Max Drawdown (3Y) | -75.32% |
| Sharpe Ratio (1Y) | 0.30 |
| Correlation with SPY (1Y) | 0.12 |
| 50-Day Average | $21.43 |
| 200-Day Average | $29.30 |
| 52-Week Range | $15.94 to $40.65 |
| RSI (14 Days) | 40.2 |
| Average Volume (20 Days) | 628.37K |
The 5-year change compares month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 23.93x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 23.93x |
|---|---|
| Quick Ratio | 23.93x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -24.51% over the last 12 months, against a 5-year average of -27.10%.
| Return on Equity (ROE) | -24.51% |
|---|---|
| Return on Assets (ROA) | -23.34% |
| ROE (5Y Average) | -27.10% |
| ROA (5Y Average) | -25.24% |
| ROIC (5Y Average) | -40.47% |
Scores
TYRA has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Piotroski F-Score | 1 of 9 |
|---|---|
| Piotroski Strength | Weak |
Income Statement
Revenue was $0 over the last 12 months.
| Revenue | $0 |
|---|---|
| Revenue Growth (YoY) | -100.00% |
| Gross Profit | -$132.00K |
| Operating Income | -$182.40M |
| Pretax Income | -$169.82M |
| Net Income | -$169.82M |
| Reported EPS (TTM) | -$2.64 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 95.23% of the $727.53M in total assets.
| Cash and Equivalents | $456.02M |
|---|---|
| Total Debt | $0 |
| Net Cash | $456.02M |
| Net Cash Per Share | $6.60 |
| Working Capital | $681.88M |
| Shareholder Equity | $692.84M |
| Book Value Per Share | $10.03 |
| Total Assets | $727.53M |
| Total Liabilities | $34.68M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $301.00K of capital spending, operating cash flow left -$119.78M of free cash flow.
| Operating Cash Flow | -$119.48M |
|---|---|
| Capital Expenditures | $301.00K |
| Free Cash Flow | -$119.78M |
| FCF Per Share | -$1.74 |
| Depreciation and Amortization | $538.00K |
Trailing 12 months through Sep 30, 2026.
Growth
| Book Value Per Share Growth (2Y CAGR) | -4.36% |
|---|---|
| Tangible Book Per Share Growth (2Y CAGR) | -4.36% |
Dividends and Yields
TYRA does not pay a dividend. Its free cash flow yield is -8.86%.
| FCF Yield | -8.86% |
|---|---|
| Buyback Yield | -40.43% |
| Shareholder Yield | -40.43% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
Frequently Asked Questions About TYRA
What is TYRA's market cap?
Tyra Biosciences has a market cap of $1.38B. Its enterprise value, which adds debt and subtracts cash, is $927.37M.
How many shares of TYRA are outstanding?
Tyra Biosciences has 69.08M shares outstanding. The count is up 15.77% from a year earlier.
Does TYRA pay a dividend?
No. Tyra Biosciences does not pay a dividend.
How much debt does TYRA have?
Tyra Biosciences has $0 of total debt and $456.02M of cash and equivalents, a net cash position of $456.02M.
TYRA pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Competitors